MA37618B1 - Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx - Google Patents

Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Info

Publication number
MA37618B1
MA37618B1 MA37618A MA37618A MA37618B1 MA 37618 B1 MA37618 B1 MA 37618B1 MA 37618 A MA37618 A MA 37618A MA 37618 A MA37618 A MA 37618A MA 37618 B1 MA37618 B1 MA 37618B1
Authority
MA
Morocco
Prior art keywords
heptane
fluor
receptor agonists
alx receptor
bridged derivatives
Prior art date
Application number
MA37618A
Other languages
English (en)
Other versions
MA37618A1 (fr
Inventor
Olivier Corminboeuf
Davide Pozzi
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA37618A1 publication Critical patent/MA37618A1/fr
Publication of MA37618B1 publication Critical patent/MA37618B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne des dérivés pontés fluorés de spiro[2.4]heptane de formule (i), où n et r
MA37618A 2012-05-16 2013-05-14 Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx MA37618B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168322 2012-05-16
PCT/IB2013/053976 WO2013171694A1 (fr) 2012-05-16 2013-05-15 Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Publications (2)

Publication Number Publication Date
MA37618A1 MA37618A1 (fr) 2016-12-30
MA37618B1 true MA37618B1 (fr) 2017-08-31

Family

ID=48699893

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37618A MA37618B1 (fr) 2012-05-16 2013-05-14 Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Country Status (23)

Country Link
US (1) US9139524B2 (fr)
EP (1) EP2850060B1 (fr)
JP (1) JP6101789B2 (fr)
KR (1) KR20150013285A (fr)
CN (1) CN104321309B (fr)
AR (1) AR091059A1 (fr)
AU (1) AU2013261091B2 (fr)
BR (1) BR112014028358A2 (fr)
CA (1) CA2871336A1 (fr)
CL (1) CL2014002918A1 (fr)
EA (1) EA025264B1 (fr)
ES (1) ES2595219T3 (fr)
HK (1) HK1208441A1 (fr)
IL (1) IL235660A0 (fr)
MA (1) MA37618B1 (fr)
MX (1) MX355221B (fr)
NZ (1) NZ702971A (fr)
PH (1) PH12014502465A1 (fr)
PL (1) PL2850060T3 (fr)
SG (1) SG11201406971WA (fr)
TW (1) TWI579269B (fr)
WO (1) WO2013171694A1 (fr)
ZA (1) ZA201409249B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640699B1 (fr) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Dérivés d'esters de spiro[2.4]heptane pontés
CN103249413B (zh) 2010-12-07 2015-11-25 埃科特莱茵药品有限公司 作为脂氧素(alx)受体激动剂的羟基化氨基三唑衍生物
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
RU2016105310A (ru) * 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
AU2015259403B2 (en) 2014-05-13 2017-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
EP3331884B1 (fr) 2015-05-27 2020-06-17 Kyorin Pharmaceutical Co., Ltd. Dérivé de l'urée ou sel pharmacologiquement acceptable de ce dernier
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN111233751B (zh) * 2020-03-25 2021-02-02 丽水绿氟科技有限公司 一种3,3-二氟-4-氨基哌啶类化合物及其衍生物的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500133A (ja) * 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド オキシトシンのアンタゴニストである置換ピペラジニル樟脳誘導体
WO2003082314A2 (fr) 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
WO2005040120A1 (fr) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Derives de tetrahydropyridine
CA2544983A1 (fr) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
EP2139888A2 (fr) 2007-03-28 2010-01-06 Array Biopharma, Inc. Composés imidazoý1,2-a¨pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
RU2492167C2 (ru) 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
JP5510945B2 (ja) * 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Ａｌｘ受容体及び／又はｆｐｒｌ２アゴニストとしての架橋スピロ［２．４］ヘプタン誘導体
EP2440555B1 (fr) 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Dérivés fluorés de l'aminotriazole
CN102803237B (zh) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
EP2585054A1 (fr) 2010-06-24 2013-05-01 Allergan, Inc. Dérivés d'acides cycloalkyl- et cycloalcényl-1,2-dicarboxyliques présentant une activité agoniste ou antagoniste du récepteur fprl-1
EP2640699B1 (fr) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Dérivés d'esters de spiro[2.4]heptane pontés
US8846733B2 (en) 2010-12-07 2014-09-30 Actelion Pharmaceuticals Ltd. Oxazolyl-methylether derivatives as ALX receptor agonists
CN103249413B (zh) 2010-12-07 2015-11-25 埃科特莱茵药品有限公司 作为脂氧素(alx)受体激动剂的羟基化氨基三唑衍生物
EP2731931A1 (fr) * 2011-07-11 2014-05-21 Allergan, Inc. Dérivés polycycliques de pyrrolidine-2,5-dione en tant que modulateurs du récepteur fprl-1 (récepteur de n-formyl peptide de type 1)
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
KR102290134B1 (ko) 2013-03-06 2021-08-17 알러간, 인코포레이티드 안구 염증성 질환을 치료하기 위한 포르밀 펩타이드 수용체 2의 작용제의 용도
CA2899804A1 (fr) 2013-03-06 2014-09-12 Allergan, Inc. Utilisation d'agonistes du recepteur 2 de peptide formyle pour le traitement de maladies dermatologiques

Also Published As

Publication number Publication date
US20150118258A1 (en) 2015-04-30
EP2850060A1 (fr) 2015-03-25
TW201348198A (zh) 2013-12-01
EP2850060B1 (fr) 2016-07-13
AU2013261091B2 (en) 2017-04-06
MX355221B (es) 2018-04-10
CN104321309A (zh) 2015-01-28
MA37618A1 (fr) 2016-12-30
PH12014502465A1 (en) 2014-12-22
AR091059A1 (es) 2014-12-30
CA2871336A1 (fr) 2013-11-21
ZA201409249B (en) 2016-09-28
JP6101789B2 (ja) 2017-03-22
BR112014028358A2 (pt) 2020-07-21
WO2013171694A1 (fr) 2013-11-21
US9139524B2 (en) 2015-09-22
CN104321309B (zh) 2016-06-22
CL2014002918A1 (es) 2015-02-06
JP2015516463A (ja) 2015-06-11
HK1208441A1 (en) 2016-03-04
MX2014013829A (es) 2015-02-04
PL2850060T3 (pl) 2017-01-31
EA201401259A1 (ru) 2015-04-30
SG11201406971WA (en) 2014-11-27
TWI579269B (zh) 2017-04-21
NZ702971A (en) 2016-09-30
KR20150013285A (ko) 2015-02-04
ES2595219T3 (es) 2016-12-28
IL235660A0 (en) 2015-02-01
EA025264B1 (ru) 2016-12-30
AU2013261091A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MA37618A1 (fr) Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
MA35905B1 (fr) Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens
MA37940A2 (fr) Nouveaux dérivés bicycliques
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA35357B1 (fr) Composes de type anilines
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
EA201591008A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA34078B1 (fr) Derives d'arylethynyle
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MX2015016495A (es) Compuestos de 3,4-dihidroisoquinolin-2 (1h)-ilo.
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA38112B1 (fr) Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA38460B1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA38555A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA34840B1 (fr) Dérivés monoterpènes de chalcone ou de dihydrochalcone, et leur utilisation en tant qu'agents de dépigmentation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
IN2014DN05972A (fr)
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MX360699B (es) Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.